Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel

Not Applicable

Completed

• Conditions: Tumors

• Registration Number: NCT01448759
• Lead Sponsor: Institut Curie

Brief Summary

The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.

Detailed Description

In this study, there is no experimental treatment, or experimental care.

Study Timeline

• Study Start: 2011-10
• Study First Submitted: 2011-10-06
• Study First Submitted QC: 2011-10-06
• Study First Posted: 2011-10-07
• Primary Completion: 2012-02
• Study Completion: 2012-02
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-23
• Last Update Posted: 2015-04-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule.
• Patient with bitherapy are eligible only if the taxane is the first infusion.
• All type of tumor.
• Age>18 years old.
• Signed written informed consent.

Exclusion Criteria

• Patient under 18.
• Patient with bitherapy, if docetaxel or paclitaxel is not administered first.
• Patient deprived of liberty.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Evaluation of plasma alcohol	One year	Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)

Trial Locations

Locations (1)

Institut Curie; 🇫🇷 Paris, France